Abstract
Diabetic retinopathy is together with the diabetic macular edema the most common cause of vision loss in the working population. It is also the most common diabetic microvascular abnormality.
Aflibercept is approved for the diabetic macular edema treatment, it is a recombinant fusion protein, binding VEGF A, B, and P1GF. The efficacy and safety of the treatment comparing with the laser treatment were set by VIVID-DME and VISTA-DME studies.
The T DRCR.net study protocol confirmed the efficacy of aflibercept, ranibizumab, and bevacizumab in the treatment of diabetic macular edema. The best results in the whole group were obtained if using aflibercept, especially in the group of patients with worse initial visual acuity.
In all three studies, the safety of intraviteraly applied aflibercept was proven.